{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:55:08Z","timestamp":1790013308553,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T00:00:00Z","timestamp":1516924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jaad.2018.01.027","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:19:22Z","timestamp":1517480362000},"page":"1156-1163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial"],"prefix":"10.1016","volume":"78","author":[{"given":"Zoe Diana","family":"Draelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Grekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne Mraz","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kempers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Alvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.01.027_bib1","first-page":"725","article-title":"Diagnosis and treatment of rosacea: state of the art","volume":"11","author":"Baldwin","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib2","series-title":"Rosacea riddle now threatens more than 16 million Americans [press release]","year":"2010"},{"key":"10.1016\/j.jaad.2018.01.027_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","article-title":"An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes","volume":"169","author":"Tan","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea: pathophysiology and treatment","volume":"130","author":"Wilkin","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2014.05.036","article-title":"The psychological impact of rosacea and the influence of current management options","volume":"71","author":"Moustafa","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","article-title":"The molecular pathology of rosacea","volume":"55","author":"Yamasaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2018.01.027_bib9","first-page":"26","article-title":"Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib10","first-page":"277","article-title":"Consensus recommendations from the American Acne and Rosacea Society on the management of rosacea, part 2: a status report on topical agents","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2018.01.027_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40257-015-0156-2","article-title":"New and emerging treatments for rosacea","volume":"16","author":"Gold","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","article-title":"Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline","volume":"143","author":"Shanler","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib13","series-title":"Rhofade [package insert]","year":"2017"},{"key":"10.1016\/j.jaad.2018.01.027_bib14","unstructured":"Stein-Gold L, Kircik LH, Draelos ZD, et al. Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the two phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. In press."},{"key":"10.1016\/j.jaad.2018.01.027_bib15","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","article-title":"Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy?","volume":"69","author":"Del Rosso","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0031-6997(24)01495-9","article-title":"Vascular adrenoceptors: an update","volume":"53","author":"Guimaraes","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaad.2018.01.027_bib17","first-page":"825","article-title":"Thermoregulatory and thermal control in the human cutaneous circulation","volume":"2","author":"Johnson","year":"2010","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.jaad.2018.01.027_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdermsci.2014.04.002","article-title":"Vasoconstriction and anti-inflammatory properties of the selective \u03b1-adrenergic receptor agonist brimonidine","volume":"75","author":"Piwnica","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2018.01.027_bib19","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.01.027_bib20","series-title":"Mirvaso [package insert]","year":"2016"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:16Z","timestamp":1759272376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218301464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0190962218301464"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.027","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732615062.793552714","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}